How do Prolia and Fosamax work differently?
Prolia (denosumab) is a monoclonal antibody injected every six months that blocks RANKL, a protein involved in bone breakdown, rapidly reducing bone resorption.[1] Fosamax (alendronate), a weekly oral bisphosphonate, binds to bone and inhibits osteoclasts, slowing bone loss over time.[1][2] Prolia acts faster on high-turnover bone sites like the spine and hip, while Fosamax builds effects gradually.
Which one increases bone density more?
Clinical trials show Prolia boosts bone mineral density (BMD) more than Fosamax. In a head-to-head study of postmenopausal women, Prolia increased lumbar spine BMD by 3.5% at one year versus 1.1% for Fosamax; hip BMD rose 2.0% versus 0.8%.[3] Over three years, Prolia's gains held at 9.2% spine BMD versus 6.2% for bisphosphonates like Fosamax in meta-analyses.[4] Prolia excels in high-risk patients with prior fractures.
What do fracture risk reductions look like?
Prolia cuts vertebral fracture risk by 68% over three years (FREEDOM trial), nonvertebral by 20%, and hip by 40%.[1] Fosamax reduces vertebral fractures by 47% and hip by 51% (FIT trial), but effects wane after 3-5 years.[2][5] Prolia shows stronger vertebral protection; Fosamax matches or edges out on hip fractures in some populations, though real-world data varies by adherence.
Common side effects and safety concerns
Both carry osteonecrosis of the jaw (ONJ) risk (0.04% for Prolia, rare for Fosamax) and atypical femoral fractures with long-term use.[1][2] Prolia uniquely risks rapid bone loss and multiple fractures if stopped abruptly without follow-on therapy.[6] Fosamax causes more gastrointestinal issues like esophagitis (up to 10% nonadherent users).[2] Prolia requires injections, increasing infection risk slightly (2-3% higher).[1] No head-to-head mortality difference.
Who gets prescribed Prolia over Fosamax?
Prolia suits high-risk cases: severe osteoporosis, prior fractures, or bisphosphonate failure.[7] Guidelines (e.g., NOF, Endocrine Society) recommend bisphosphonates like Fosamax first-line for most due to oral ease, cost, and long track record.[7][8] Switch to Prolia if BMD doesn't improve or fractures continue. Fosamax fits milder cases or glucocorticoid-induced osteoporosis.
Cost and access factors
Fosamax generics cost $10-50/month; Prolia runs $1,500-2,000 per injection (six-month supply).[9] Insurance often covers both, but Prolia needs prior authorization for high-risk patients. Long-term: Fosamax has a 10-year "drug holiday" option; Prolia demands seamless transition to avoid rebound.
Bottom line: Is one clearly better?
Neither is universally "better"—Prolia delivers superior BMD gains and vertebral protection for high-risk patients but with higher cost, injection burden, and discontinuation risks.[3][6] Fosamax works well first-line for most, cheaper and oral, though less potent.[5][7] Choice depends on fracture history, adherence, and kidney function (Fosamax avoids in GFR<35).[1][2] Consult a doctor for DEXA-guided personalization.
Sources
[1]: Prolia prescribing information
[2]: Fosamax prescribing information
[3]: Bone HG et al., J Bone Miner Res 2011;26:1705-1714
[4]: McClung MR et al., J Bone Miner Res 2013;28:2222-2230
[5]: Black DM et al., NEJM 1996;335:1535-1541
[6]: Anastasilakis AD et al., J Bone Miner Res 2015;30:365-375
[7]: NOF Clinician's Guide 2021
[8]: Endocrine Society Guidelines 2020
[9]: GoodRx pricing data, 2023